In 2026, AI will no longer be a simple experiment for life sciences but a transformation engine integrated into the heart of the industry.
After a period of experimentation, life sciences are entering a crucial new phase in the adoption of AI. The industry is moving away from hype-driven pilot projects toward proven, value-driven applications that improve how therapies are developed, launched and delivered to patients. It is becoming clearly evident that the real differentiator will not just be the number of algorithms, but how companies rethink their teams, processes and data to unlock the potential of AI.
From transforming business models to accelerating clinical research, 2026 will be the year when organizations integrate AI into their core operations with discipline and determination. Here are five predictions for how this change will take shape across the value chain.
1. Change in people and processes will enable AI to create value
After years of large-scale pilot projects with limited return on investment, the industry will step back from an “AI at all costs” approach. Organizations will prioritize high-value AI use cases focused on core and critical business processes and train their workforce in new ways of working.
High-value AI projects will significantly improve efficiency and productivity. To take full advantage of this, the focus will need to be on teams and process changes to achieve real results. For example, an AI agent that helps sales teams quickly evaluate content for medical, legal and regulatory review will ensure accuracy, brand and industry compliance to expedite reviews. This will allow highly qualified experts to focus on higher value-added tasks.
With a targeted, replicable approach, organizations can set measurable goals based on business value, work with specific operational user groups on AI adoption, adapt people and processes to new ways of working, and measure meaningful results.
2. Industry-specific AI will orchestrate business connections
Industry-specific AI, integrated into compliant and connected platforms and applications, will prove to be the critical enabler to coordinate business, marketing and healthcare activities. AI agents with direct, secure access to data, content, and business processes will surface insights and connect workflows across teams with seamless omnichannel orchestration.
AI agents will keep the entire sales team informed to build more constructive relationships with healthcare professionals. For example, a sales representative can easily record voice notes while an AI agent checks for compliance. Another AI agent will automatically relay this information to the right sales team members at the right time for better relationship management. AI can then be used to identify critical business themes and key insights from the entire voice notes — a valuable new data set — to guide branding and go-to-market strategy.
These agentic AI capabilities will work together to help sales teams increase their productivity and improve the effectiveness of their customer engagement.
3. The industry is moving towards more agile and dynamic data to ensure successful launches
The pace of launches is driving a shift towards faster use of data, with processes catching up to enable daily access to data. A successful launch requires rapid analysis and decision-making, such as reallocating field resources when a healthcare professional or territory exceeds or falls short of planned treatment goals. This has created an urgent need for biopharmaceutical and emerging biotechnology companies to implement rapid actions from alerts and targeted data analysis rather than waiting for reports.
Small biotech companies, whose survival depends on bringing a new treatment to market, are the driving force behind the agility that the industry will adopt. In 2026, some companies will go from a 14-day data analysis cycle to just 14 hours before activation. This is a big step forward from traditional weekly, monthly or quarterly data. This shift not only enables biopharmaceutical companies to launch successfully, but also to make better decisions with industry-specific AI. Real-time reallocations, especially during the first 18 months of a launch, will help get new medicines more quickly to patients who need them.
4. Lab assistants with agentic AI will promote connectivity and speed
Labs will move beyond chatbots to incorporate agentic lab assistants that bridge very specific tasks in a regulated environment. Quality control labs are now looking at the effectiveness potential of AI agents and working to implement them across teams and processes. However, quality control laboratory technology ecosystems are fragmented and paper-based processes persist. Companies will modernize and consolidate systems, standardize their data and workflows, and integrate quality assurance to take advantage of the productivity gains offered by quality control-specific AI.
Lab analysts will work alongside agents who can initiate workflows, summarize results, and observe and analyze trends. This will advance proactive risk management by identifying issues early and driving proper execution from the start. The result will be a highly efficient and effective quality control laboratory where people and agents work together to shorten production cycle times.
5. Flow of data from clinical trials will facilitate recruitment and improve patient access and experience
The flow of clinical data between sites and sponsors will enable faster and more efficient trials. Information relating to the studies will be transmitted directly to doctors in order to connect their patients with relevant research. New integrated artificial intelligence will link trial data across sponsors and sites so doctors can research treatment and trial options based on patients’ health conditions or test results. This direct approach to physicians will reduce the industry’s reliance on sites to find study participants, in order to more quickly achieve recruitment goals and improve patient access to clinical trials.
With reduced patient recruitment requirements and modern technology, sites will realize the promise of eliminating paper and manual verification of source data for clinical researchers. eSource tools will better connect upstream and downstream clinical data sources, first with electronic health records so that patient health data can more effectively merge with trial data. When connected to an electronic data capture (EDC) system, source forms will be defined by a description of the trial, allowing data to be transmitted more quickly, and with greater clarity, to the sponsor. This data flow will streamline study visits for patients and advance trials for sites and sponsors.
AI is no longer an experimental technology on the fringes of the company. It is quickly becoming the neural pathway that connects people, processes and data across the entire business and development ecosystem. But the organizations that will be ahead in 2026 will not be those seeking the most spectacular tools. They will be the ones who make deliberate choices: focusing on high-value use cases, preparing teams for new ways of working, and putting in place the connected foundations that enable AI to operate safely, compliantly, and at scale.
The next wave of innovation in life sciences will not only be defined by the capabilities of AI, but also by how intelligently and responsibly companies implement it. Those that succeed will benefit from faster insights, smarter execution and, ultimately, better patient outcomes.
